ScoreWhy is Glenmark Pharmaceuticals Ltd. ?
1
Poor long term growth as Net Sales has grown by an annual rate of 4.85% and Operating profit at 7.80% over the last 5 years
2
Stock is technically in a Mildly Bearish range
- The stocks Bollinger Band and KST technical factors are also Bearish
3
With ROE of -5.9, it has a Very Expensive valuation with a 4.6 Price to Book Value
- The stock is trading at a premium compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of 31.12%, its profits have fallen by -11.8%
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Drugs)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is Glenmark Pharma for you?
Medium Risk, High Return
Absolute
Risk Adjusted
Volatility
Glenmark Pharma
31.41%
1.00
31.23%
SENSEX
0.45%
0.03
14.48%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
4.85%
EBIT Growth (5y)
7.80%
EBIT to Interest (avg)
4.54
Debt to EBITDA (avg)
1.88
Net Debt to Equity (avg)
0
Sales to Capital Employed (avg)
1.01
Tax Ratio
100.00%
Dividend Payout Ratio
-4.70%
Pledged Shares
0
Institutional Holding
37.39%
ROCE (avg)
13.43%
ROE (avg)
8.62%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
158
Industry P/E
33
Price to Book Value
4.60
EV to EBIT
21.73
EV to EBITDA
16.88
EV to Capital Employed
4.65
EV to Sales
2.95
PEG Ratio
NA
Dividend Yield
0.18%
ROCE (Latest)
11.39%
ROE (Latest)
-5.86%
Loading Valuation Snapshot...
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
Bullish
Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend21What is working for the Company
PAT(HY)
At Rs 702.17 cr has Grown at 361.33%
PBT LESS OI(Q)
At Rs 425.20 cr has Grown at 290.8% (vs previous 4Q average
ROCE(HY)
Highest at 16.70%
CASH AND CASH EQUIVALENTS(HY)
Highest at Rs 1,820.24 cr
0What is not working for the Company
NO KEY NEGATIVE TRIGGERS
Loading Valuation Snapshot...
Here's what is working for Glenmark Pharma
Profit Before Tax less Other Income (PBT) - Quarterly
At Rs 425.20 cr has Grown at 290.8% (vs previous 4Q average)
over average PBT of the previous four quarters of Rs 108.81 CrMOJO Watch
Near term PBT trend is very positive
PBT less Other Income (Rs Cr)
Profit After Tax (PAT) - Quarterly
At Rs 347.96 cr has Grown at 251.7% (vs previous 4Q average)
over average PAT of the previous four quarters of Rs -229.31 CrMOJO Watch
Near term PAT trend is very positive
PAT (Rs Cr)
Cash and Cash Equivalents - Half Yearly
Highest at Rs 1,820.24 cr
in the last six half yearly periodsMOJO Watch
Short Term liquidity is improving
Cash and Cash Equivalents
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
